Urinary cyclophilin A as an early marker of chronic kidney disease with underlying type 2 diabetes

Patutong Chatchawal,Patcharaporn Tippayawat,Thidarat Somdee,Sawinee Ngernpimai,Molin Wongwattanakul,Nattaya Sae-ung,Sirirat Anutrakulchai,Ratthaphol Kraiklang
DOI: https://doi.org/10.1038/s41598-024-73994-5
IF: 4.6
2024-10-06
Scientific Reports
Abstract:Cyclophilin A (CypA) is a novel renal inflammation biomarker, with levels altered in various diseases, particularly in patients with diabetes mellitus (DM) and kidney damage. This study aimed to investigate the correlation between urinary cyclophilin A (uCypA) and chronic kidney disease (CKD) conditions with and without type 2 diabetes mellitus (T2DM) using an in-house enzyme-linked immunoassay (ELISA) method. A uCypA strip-test prototype was also developed. An indirect ELISA was performed to determine the uCypA levels. A 0.48 μg/mL uCypA cutoff differentiated healthy patients from those with early-stage CKD (stages I and II). The uCypA levels were significantly increased in patients with progression of renal deterioration, especially in the T2DM with late-stage CKD group, compared to the control group. Fasting blood sugar (FBS), estimated glomerular filtration rate (eGFR), albumin/creatinine ratio, and metformin use were associated with uCypA levels. Multinomial logistic regression analysis revealed an association between uCypA levels and T2DM diagnosed for over five years and early-stage CKD. This finding shows that uCypA could be used as a biomarker for distinguishing early-stage CKD as well as T2DM complications, which is beneficial for patients to be aware of their health status and change their behavior to slow kidney deterioration.
multidisciplinary sciences
What problem does this paper attempt to address?